Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Genetics Said Q1 Losses Widened as Spending Overpowered Strong Revenue Growth

NEW YORK, Nov. 6 - Myriad Genetics yesterday said that greater spending in its fiscal first quarter overpowered strong revenue growth to widen net loss.

 

Total receipts in the period ended Sept. 30 increased to $15.5 million from $13.2 million on year ago. Driving that growth were receipts from Myriad's predictive medicine divisions, which grew by $2.2 million, or 43 percent, on sales of the BRACAnalysis breast cancer test and the Colaris products for colon and uterine cancer.

 

However, revenue from combined research activities in the current first quarter dipped to $7.6 million from $7.7 million last year as Myriad shifted more of its focus to internal drug-development programs.

 

R&D spending in the quarter increased 33 percent to $10.9 million. Myriad said the increase was due mainly to costs associated with developing its therapeutic pipeline, which contains 15 drug candidates.

 

First-quarter SG&A spending also jumped by 37 percent to $7.7 million, reflecting an unspecified increase in sales force, Myriad said.

 

Consequently, net loss for the first quarter 2002 swelled to $5.3 million, or $.22 per share, from $1.2 million, or $.05 per share, year over year, Myriad said.

 

The company said it had roughly $103.7 million in cash and marketable investment securities as of Sept. 30.

 

Click here for more information.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.